[14C]-AZD5305 microtracer

Phase 1

[14C]-AZD5305 microtracer is one of 2 therapeutic programs targeting Advanced or Metastatic Solid Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Advanced or Metastatic Solid TumorRecruiting

Advanced or Metastatic Solid TumorPhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in Advanced or Metastatic Solid Tumor

#DrugCompanyPhaseTrials

Saruparib

AstraZeneca

Phase 1

1 2

[14C]-AZD5305 microtracer

AstraZeneca

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Advanced or Metastatic Solid Tumor

NCT06713369

Clinical

Trials by Indication[1]

Advanced or Metastatic Solid Tumor1 trial

A Phase I, Open-label Study to Assess the Absolute Bioavailability of Saruparib (AZD5305) and Absorption, Distribution, Metabolism, and Excretion (ADME) of [14C]-Saruparib ([14C]-AZD5305) in Patients With Advanced Solid Malignancies

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT06713369·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for [14C]-AZD5305 microtracer. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for [14C]-AZD5305 microtracer. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: AstraZeneca

[14C]-AZD5305 microtracer

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Advanced or Metastatic Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News